Skip to content

BioCryst Pharmaceuticals BCRX Other Non-Current Assets

Other Non-Current Assets at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$61M-2.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$11.58M+12.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$256K0.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's other non-current assets?
BioCryst Pharmaceuticals (BCRX) reported other non-current assets of $19.7M in Q1 2026.
How has BioCryst Pharmaceuticals's other non-current assets changed year-over-year?
BioCryst Pharmaceuticals's other non-current assets increased by 306.1% year-over-year, from $4.85M to $19.7M.
What is the long-term trend for BioCryst Pharmaceuticals's other non-current assets?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's other non-current assets has grown at a 8.3% compound annual growth rate (CAGR), from $3.8M to $5.67M.
What does other non-current assets mean?
This category captures long-term assets that do not fit into standard classifications like property, plant, equipment, or intangible assets. It may include long-term deposits, deferred tax assets, or other miscellaneous non-current investments. It represents the residual value of long-term resources held by the company.